Table 2.
Baseline characteristics of FACT participants with PTHM measures at baseline in 400 µg FA and placebo groups
| 400 µg FA (n = 107) | Placebo (n = 60) | ||
|---|---|---|---|
| Characteristic | Median (IQR) | Median (IQR) | Pa |
| Age (years) | 38 (34–46) | 38 (33–44) | 0.29 |
| BMI (kg/m2)b | 19.3 (17.8–21.0) | 19.5 (18.1–22.1) | 0.37 |
| RBC Folate (nmol/L)c | 424 (360–617) | 472 (357–548) | 0.74 |
| Plasma Folate (nmol/L) | 13 (8–19) | 13 (10–17) | 0.53 |
| Plasma Vitamin B12 (pmol/L) | 213 (154–296) | 220 (150–323) | 0.76 |
| Plasma Choline (µmol/L) | 11.0 (9.9–13.0) | 10.9 (9.7–13.1) | 0.86 |
| Plasma Betaine (µmol/L) | 42.4 (35.1–51.9) | 43.4 (34.1–54.7) | 0.84 |
| Plasma Hcys (µmol/L) | 11.4 (8.6–15.5) | 11.7 (8.9–16.0) | 0.77 |
| Blood Arsenic (µg/L) | 8.4 (6.0–12.7) | 8.7 (6.1–11.5) | 0.83 |
| bSe (µg/L) | 135 (122–152) | 136 (124–150) | 0.93 |
| uCr (mg/dL) | 46 (32–83) | 40 (20–62) | 0.03 |
| H3K36me2d, relative % of total H3 | 1.48 (1.28–1.86) | 1.56 (1.37–1.73) | 0.61 |
| H3K36me3e, relative % of total H3 | 1.62 (1.21–2.07) | 1.67 (1.38–2.00) | 0.51 |
| H3K79me2f, relative % of total H3 | 1.20 (1.06–1.68) | 1.16 (0.96–1.59) | 0.18 |
| Folate Deficient (%)g | 26.2 | 18.3 | 0.25 |
| Vitamin B12 Deficient (%)h | 23.4 | 26.7 | 0.63 |
| HHcys (%)i | 39.3 | 46.7 | 0.35 |
| Male (%) | 50.5 | 51.7 | 0.88 |
| Ever Smoker (%)j | 28.6 | 31.7 | 0.68 |
| Education > 5 years (%) | 22.4 | 16.7 | 0.37 |
| Own TV (%) | 42.1 | 40.0 | 0.80 |
a
P was from Wilcoxon rank-sum test and Chi Square test for difference between 400 µg FA and placebo groups for continuous and categorical variables, respectively
b
n = 104 for 400 µg FA, n = 59 for Placebo group
c
n = 103 for 400 µg FA group
d
n = 105 for 400 µg FA, n = 56 for Placebo group
e
n = 102 for 400 µg FA, n = 57 for Placebo group
f
n = 106 for 400 µg FA, n = 60 for Placebo group
g
Plasma folate < 9 nmol/L
h
Plasma vitamin B12 < 151 pmol/L
i
Plasma Hcys > 13 µmol/L
j
n = 104 for 400 µg FA